LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to stop head and neck cancer from returning
Disease control Recruiting nowThis large Phase 3 trial tests whether an experimental immunotherapy drug called volrustomig can help prevent cancer from returning in people with locally advanced head and neck cancer who have finished chemoradiation. About 1,145 participants will either receive volrustomig or b…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Nanoparticles boost radiation to fight head and neck cancer in elderly
Disease control Recruiting nowThis phase 3 trial tests whether injecting NBTXR3 nanoparticles into tumors before radiation therapy can improve outcomes for elderly patients with advanced head and neck cancer who cannot receive chemotherapy. About 500 participants will be randomly assigned to receive either ra…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New cocktail aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis phase II trial tests whether adding the targeted drug nimotuzumab to immunotherapy and chemotherapy before surgery can improve outcomes for people with locally advanced head and neck cancer. About 182 participants will receive the combination or standard treatment. The main …
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo aims to boost chemoradiation for head and neck cancer
Disease control Recruiting nowThis early-phase study tests whether adding the experimental drug ipatasertib to standard chemotherapy and radiation is safe and effective for people with advanced head and neck cancer. Ipatasertib may help stop cancer cell growth. About 46 participants will receive the combinati…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Biomarker-Guided trial aims to find best chemo for head and neck cancer
Disease control Recruiting nowThis study tests which chemotherapy combination works better when given with radiation for advanced head and neck cancer. About 120 adults with stage III or IV disease will receive either cisplatin or a mix of docetaxel and cetuximab. Researchers will also check if a tumor marker…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Christopher Wilke • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Promising combo aims to boost Cancer-Free survival in head and neck cancer
Disease control Recruiting nowThis phase 3 trial is testing whether adding a targeted drug (becotatug vedotin) to standard immunotherapy (a PD-1 inhibitor) before and after surgery can help people with a certain type of head and neck cancer live longer without the cancer coming back. About 430 adults with EGF…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug duo shows promise against tough head and neck cancer
Disease control Recruiting nowThis study tests whether adding an immunotherapy drug (pucotenlimab) to a targeted therapy (MRG003) before standard chemoradiation can shrink tumors more effectively in people with advanced head and neck cancer. About 106 adults aged 18-75 with locally advanced squamous cell carc…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New cocktail aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis phase 2 trial tests a new combination of drugs—imaxitinib, chemotherapy, and immunotherapy—given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors more effectively, making surgery easier or possible for patients whose can…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New immune therapy aims to keep head and neck cancer at bay
Disease control Recruiting nowThis study tests whether giving additional immune therapy after surgery can help prevent head and neck cancer from coming back. It includes 268 adults who already had a good response to initial treatment. The goal is to see if this approach improves survival and is safe.
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New combo therapy aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis phase II trial is testing whether combining low-dose radiotherapy with the immunotherapy drug Toripalimab before surgery can improve outcomes for people with advanced head and neck squamous cell carcinoma. About 22 participants will receive two cycles of the combination, the…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Xiwei XU • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could less surgery be better for head and neck cancer patients?
Disease control Recruiting nowThis study is testing whether people with advanced head and neck cancer who respond well to immunotherapy can have a smaller, less invasive surgery instead of the standard extensive surgery. The goal is to see if the smaller surgery works just as well at controlling the cancer wh…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Qunxing Li,MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Immunotherapy-Chemo cocktail aims to shrink head and neck tumors before treatment
Disease control Recruiting nowThis study tests whether combining the immunotherapy drug tislelizumab with chemotherapy (paclitaxel, cisplatin, 5-FU) can shrink advanced head and neck tumors before surgery or chemoradiation. About 29 adults with stage III-IVb cancer will receive the combo for three cycles. Res…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 26, 2026 14:12 UTC
-
Blood test may spot hidden cancer after chemoradiation
Knowledge-focused Recruiting nowThis study looks at whether a simple blood test can find leftover cancer cells in people treated for advanced head and neck cancer. About 59 participants will give blood samples one and three months after finishing chemoradiotherapy. Researchers will compare the blood test result…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Centre Jean Perrin • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Blood test may outshine scans for spotting hidden cancer after radiation
Knowledge-focused Recruiting nowThis study is testing whether a simple blood test that looks for tumor DNA can better detect any cancer left behind after radiation therapy for advanced head and neck cancer. Current scans often give false alarms, leading to unnecessary procedures. The study will enroll 63 adults…
Matched conditions: LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Centre Jean Perrin • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC